Author(s): Chenwei Wang1,2, Yadi Liao1, Wei He1,2, Hong Zhang1, Dinglan Zuo1, Wenwu Liu1,2, Zhiwen Yang1,2, Jiliang Qiu1,2, Yichuan Yuan1,2, Kai Li1,2, Yuanping Zhang1,2, Yongjin Wang1,2, Yunxing Shi1,2, Yuxiong Qiu1,2, Song Gao1, Yunfei Yuan1,2 and Binkui Li1,2
Correction to: J Exp Clin Cancer Res 40, 113 (2021)
https://doi.org/10.1186/s13046-021-01904-y
Following publication of the original article [1], the authors identified minor errors in Figs. 2, 3 and 5, specifically:
* Fig. 2d: image for PLC-8024 shElafin #6 at 0 h (1st row, 3rd column); correct image now used
* Fig. 3b: image for the invasion assay of Huh7 Neg and Elafin (1st and 2nd row, 5th column); correct images now used
* Fig. 3d: image for the invasion assay of Huh7 Neg CM (2nd row, 1st column); correct image now used
* Fig. 5g: images for the E-cadherin and Vimentin of Huh7-Elafin-Con (1st and 2nd row, 3rd column), and the E-cadherin of Hep3B-Neg-Con (1st row, 5th column); correct images now used
In addition, the authors revised the Supplemental Figures file during manuscript revision, but the original file was published alongside the article. The revised version has now been used, with the following changes from the original:
* Fig. S1c, additional western blots included to show Elafin protein levels in whole cell lysate (top) and condition medium (bottom)
* Fig. S6c, correct images used for invasion assay of Hep3B-Neg-U0126 (1st row, 3rd column) and invasion assay Huh7-Elafin-U0126 (2nd row, 6th column)
* Fig. S7a, correct images used for Huh7-Neg-con at 0 h (1st row, 5th column), Huh7-Elafin-Erlotinib at 0 h (1st row, 8th column), Hep3B-Elafin-Erlotinib at 48 h (3rd row, 4th column), and Huh7-Elafin-Erlotinib at 48 h (3rd row, 8th column)
The authors provided the Journal with the original data files. The corrected figures are given here. The corrections do not have...